David Parrish expects AI to be among the major talking points for a newly formed committee aimed at protecting the interests of London-based IP practitioners, firms, and their clients
Wu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent
The tie-up, which will create a firm with a combined revenue of around $2bn, will add around 10 US-based partners to Herbert Smith Freehills’s IP offering
The High Court’s decision in WaterRower v Liking could have signalled the start of a new approach to determining whether designs can benefit from copyright protection
Maohua Wang, head of the IP group at King & Wood Mallesons in China, explains how the firm’s Eversheds deal affected the IP team and how his team meets clients’ litigation needs
Firms that advise generics businesses reflect on whether they’re seeing more aggressive tactics from innovators and how they’re managing their practices